The Effects of the L/N-Type Calcium Channel Blocker (Cilnidipine) on Sympathetic Hyperactive Morning Hypertension: Results From ACHIEVE-ONE

Journal of Clinical Hypertension

Volumn 15, Issue 2, 2013, Pages 133-142

  Kario, Kazuomi ^a   Ando, Shin Ichi ^b   Kido, Hidenori ^c   Nariyama, Jin ^d   Takiuchi, Shin ^e   Yagi, Tetsuo ^f   Shimizu, Toshiki ^g   Eguchi, Kazuo ^a   Ohno, Minoru ^h   Kinoshita, Osamu ⁱ   Yamada, Takahisa ^j  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Saiseikai Futsukaichi Hospital   (Japan)

^c Meimai Central Hospital   (Japan)

^d WEST JAPAN RAILWAY COMPANY   (Japan)

^e Higashi Takarazuka Satoh Hospital   (Japan)

^f SENDAI CITY HOSPITAL   (Japan)

^g Hino Memorial Hospital   (Japan)

^h TORANOMON HOSPITAL   (Japan)

ⁱ SUWA RED CROSS HOSPITAL   (Japan)

^j OSAKA GENERAL MEDICAL CENTER   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CILNIDIPINE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL (TOPIC); DIZZINESS; DRUG EFFECT; FEMALE; FLUSHING; HEART PALPITATION; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MORNING HYPERTENSION; PRIORITY JOURNAL; PULSE RATE; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

AGED; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, N-TYPE; CIRCADIAN RHYTHM; DIHYDROPYRIDINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART RATE; HUMANS; HYPERTENSION; JAPAN; MALE; MIDDLE AGED; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 84872687160     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12042     Document Type: Article

References (36)

1. Ohkubo T, Imai Y, Tsuji I, et al. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population-based observation in Ohasama, Japan. J Hypertens. 1998;16:971-975.
2. Sega R, Facchetti R, Bombelli M, et al. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the pressioni arteriose monitorate e loro associazioni (pamela) study. Circulation. 2005;111:1777-1783.
3. Kario K, Pickering TG, Matsuo T, et al. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensives. Hypertension. 2001;38:852-857.
4. Ohkubo T, Asayama K, Kikuya M, et al. Prediction of ischaemic and haemorrhagic stroke by self-measured blood pressure at home: the Ohasama study. Blood Press Monit. 2004;9:315-320.
5. Agarwal R, Andersen MJ. Prognostic importance of clinic and home blood pressure recordings in patients with chronic kidney disease. Kidney Int. 2006;69:406-411.
6. Palatini P, Benetos A, Grassi G, et al. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension consensus meeting. J Hypertens. 2006;24:603-610.
7. Gillman MW, Kannel WB, Belanger A, et al. Influence of heart rate on mortality among persons with hypertension: the Framingham study. Am Heart J. 1993;125:1148-1154.
8. Ogihara T, Kano T, Kakinuma C. Evaluation of the inhibitory effect of dihydropyridines on n-type calcium channel by virtual three-dimensional pharmacophore modeling. Arzneimittelforschung. 2009;59:283-288.
9. Takahara A. Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovasc Ther. 2009;27:124-139.
10. Takahara A, Koganei H, Takeda T, et al. Antisympathetic and hemodynamic property of a dual l/n-type Ca(2+) channel blocker cilnidipine in rats. Eur J Pharmacol. 2002;434:43-47.
11. 2+ channel blocker cilnidipine in anesthetized dogs. Eur J Pharmacol. 2007;565:166-170.
12. Sakata K, Shirotani M, Yoshida H, et al. Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Hypertension. 1999;33:1447-1452.
13. Kosaka T, Nakagawa M, Ishida M, et al. Cardioprotective effect of an l/n-type calcium channel blocker in patients with hypertensive heart disease. J Cardiol. 2009;54:262-272.
14. Tomiyama H, Kimura Y, Kuwabara Y, et al. Cilnidipine more highly attenuates cold pressor stress-induced platelet activation in hypertension than does amlodipine. Hypertens Res. 2001;24:679-684.
15. Eguchi K, Kario K, Shimada K. Differential effects of a long-acting angiotensin converting enzyme inhibitor (temocapril) and a long-acting calcium antagonist (amlodipine) on ventricular ectopic beats in older hypertensive patients. Hypertens Res. 2002;25:329-333.
16. Eguchi K, Kario K, Hoshide Y, et al. Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients. Am J Hypertens. 2004;17:112-117.
17. Ishimitsu T, Minami J, Yoshii M, et al. Comparison of the effects of amlodipine and losartan on 24-hour ambulatory blood pressure in hypertensive patients. Clin Exp Hypertens. 2002;24:41-50.
18. Nagahama S, Norimatsu T, Maki T, et al. The effect of combination therapy with an l/n-type Ca(2+) channel blocker, cilnidipine, and an angiotensin II receptor blocker on the blood pressure and heart rate in Japanese hypertensive patients: an observational study conducted in Japan. Hypertens Res. 2007;30:815-822.
19. Yamagishi T. Beneficial effect of cilnidipine on morning hypertension and white-coat effect in patients with essential hypertension. Hypertens Res. 2006;29:339-344.
20. Imai Y, Otsuka K, Kawano Y, et al. Japanese Society of Hypertension (JSH) guidelines for self-monitoring of blood pressure at home. Hypertens Res. 2003;26:771-782.
21. Hozawa A, Ohkubo T, Kikuya M, et al. Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study. Am J Hypertens. 2004;17:1005-1010.
22. Nauman J, Janszky I, Vatten LJ, et al. Temporal changes in resting heart rate and deaths from ischemic heart disease. JAMA. 2011;306:2579-2587.
23. Ishikawa J, Kario K, Hoshide S, et al. Determinants of exaggerated difference in morning and evening blood pressure measured by self-measured blood pressure monitoring in medicated hypertensive patients: Jichi morning hypertension research (J-MORE) study. Am J Hypertens. 2005;18:958-965.
24. Kario K, Odawara M, Kimura K, et al. Nearly half of uncontrolled hypertensive patients could be controlled by high-dose titration of amlodipine in the clinical setting: the Achieve study. Curr Hypertens Rev. 2011;7:102-110.
25. Schofl C, Becker C, Prank K, et al. Twenty-four-hour rhythms of plasma catecholamines and their relation to cardiovascular parameters in healthy young men. Eur J Endocrinol. 1997;137:675-683.
26. Marfella R, Gualdiero P, Siniscalchi M, et al. Morning blood pressure peak, qt intervals, and sympathetic activity in hypertensive patients. Hypertension. 2003;41:237-243.
27. Kario K. Morning surge in blood pressure and cardiovascular risk: evidence and perspectives. Hypertension. 2000;56:765-773.
28. White WB. Importance of blood pressure control over a 24-hour period. J Manag Care Pharm. 2007;13:34-39.
29. Palatini P. Role of elevated heart rate in the development of cardiovascular disease in hypertension. Hypertension. 2000;58:745-750.
30. Fox K, Borer JS, Camm AJ, et al. Resting heart rate in cardiovascular disease. J Am Coll Cardiol. 2007;50:823-830.
31. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (shift): a randomised placebo-controlled study. Lancet. 2000;376:875-885.
32. Tanaka M. The l/n-type calcium channel blocker, cilnidipine, reduces heart rate and albuminuria in patients with type 2 diabetes. J Int Med Res. 2000;38:602-610.
33. Habeler G, Lenzhofer R, Pall H, et al. [Effectiveness and tolerance of amlodipine in treatment of patients with mild to moderate hypertension. Results of a long-term study with a new calcium antagonist]. Wien Klin Wochenschr. 1992;104:16-20.
34. Fogari R, Mugellini A, Zoppi A, et al. Differential effects of lercanidipine and nifedipine GITS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens. 2003;16:596-599.
35. Lohmeier TE, Iliescu R, Liu B, et al. Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension. 2000;59:331-338.
36. Fujita T, Ando K, Nishimura H, et al. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int. 2007;72:1543-1549.